Sotera Health Company (SHC)

Executive Summary / Key Takeaways

• Litigation Overhang Clearing: Sotera Health has settled over 1,000 ethylene oxide claims for approximately $508 million since 2023, with recent favorable verdicts and a strategic defense posture that reduces future settlement risk, removing a primary valuation constraint while the underlying business accelerates.

• Mission-Critical Infrastructure Moat: The company’s vertical integration of Cobalt-60 supply (controlling ~60% of global availability) and a 62-facility sterilization network serving 40 of the top 50 medical device companies creates pricing power evidenced by 4% pricing contributions across segments and 51% consolidated EBITDA margins that exceed direct peers.

• Operational Leverage in Action: Despite navigating EO facility enhancements and regulatory uncertainty, Sterigenics delivered 54.6% segment margins and Nelson Labs expanded margins 312 basis points to 33.3% in 2025, demonstrating management’s ability to drive profitability even while absorbing compliance costs.

• Valuation Disconnect: Trading at 10.24x EV/EBITDA versus peers at 11.7x-14.7x, SHC trades at a discount to Steris (STE) despite superior margins and growth durability, with William Blair noting potential for 45% upside if the stock re-rates toward its historical average of 12.6x.

• Cash Flow Inflection Ahead: With net leverage improving to 3.2x and capital expenditures declining from $138 million in 2025 to approximately $110 million by 2027, management targets $500-600 million in cumulative free cash flow over 2025-2027, setting up potential deleveraging, capital returns, or accretive M&A.

Setting the Scene: The Essential Last Step in Healthcare Manufacturing

Sotera Health, incorporated in 2015 through the combination of legacy businesses with roots stretching back over 90 years, occupies a non-discretionary chokepoint in the global healthcare supply chain. The company provides terminal sterilization services—the final, legally mandated step before medical devices, pharmaceuticals, and bioprocessing components can enter patient use. This is a regulatory requirement where failure to sterilize means products cannot ship, making Sotera’s 62 facilities across three segments the critical last mile between manufacturing and patient care.

The industry structure favors incumbents. The $4.5 billion sterilization services market is characterized by high barriers to entry: FDA-validated facilities require 1-2 years and $50-100 million in capital to build, nuclear materials handling demands specialized licenses, and customer quality systems mandate flawless execution. Sotera serves over 2,000 customers, including more than 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical firms, with over 90% of revenues tied to multi-year contracts. This creates a recurring revenue base that has delivered 20 consecutive years of growth through the Great Recession, COVID-19 supply chain disruptions, and now, extensive litigation.

Sotera’s competitive positioning diverges meaningfully from rivals. While Steris competes across sterilization modalities and equipment sales, and Charles River (CRL) dominates preclinical testing, Sotera’s differentiation lies in vertical integration. Through its Nordion segment, the company controls the global Cobalt-60 supply chain—the radioactive isotope powering gamma irradiation, the gold standard for sterilizing complex, high-density medical devices. This is a supply security guarantee that becomes more valuable as geopolitical tensions threaten alternative sources. The company’s end-to-end ecosystem, combining Nordion’s isotope supply, Sterigenics’ sterilization network, and Nelson Labs’ testing and advisory services, creates switching costs that manifest in 90%+ customer retention and pricing power that has sustained 3-4% annual price increases across cycles.

Technology, Products, and Strategic Differentiation: The Cobalt Moat

Sotera’s technology advantage centers on three pillars, each with distinct economic implications. First, proprietary Cobalt-60 supply through Nordion provides what no competitor can replicate. Controlling approximately 60% of global Co-60 production from nuclear reactors, Sotera ensures supply continuity while competitors face potential disruptions—particularly from Russian sources that still represent up to 20% of long-term supply for the broader market. This matters because a sterilization facility without Co-60 is idle capital, and medical device customers cannot tolerate supply interruptions. The economic implication is pricing power: Nordion maintains 57.3% segment margins while delivering 8.2% revenue growth, with 90% of revenues under multi-year contracts that include price escalators. When Westinghouse (BEP) and PSEG (PEG) begin U.S. Co-60 production via Sotera’s technology, it further insulates the supply chain while opening a domestic revenue stream that will be exempt from USMCA tariffs.

Second, multi-modal sterilization capabilities across gamma, ethylene oxide (EO), and electron beam (E-beam) reduce customer risk concentration. While EO has faced regulatory and litigation pressure, Sterigenics’ 23 gamma facilities and 8 E-beam locations allow customers to switch modalities without changing providers. This flexibility proved critical when the EPA announced stringent NESHAP rules for EO in March 2024. Rather than losing customers to in-sourcing or competitors, Sotera retained them by offering alternative modalities, evidenced by Sterigenics’ 8.3% revenue growth and 54.6% margins in 2025. The company’s investment in X-ray irradiation—a new facility opening in 2026—addresses the 16% of revenue from commercial applications (electronics, food, spices) where customers prefer X-ray’s faster processing times. While management admits this greenfield investment will generate below their 20% IRR target initially, it strategically completes the modality portfolio, enabling Sotera to serve any sterilization requirement from a single platform.

Third, integrated testing and advisory services through Nelson Labs create cross-selling opportunities that competitors cannot match. When Sotera’s scientists performed biocompatibility testing for the first FDA-cleared bionic pancreas at Nelson Labs, then sterilized the device at Sterigenics, they demonstrated a value proposition that reduces customer validation time by 20-30% compared to using separate providers. This integration drives Cross-Business Unit revenue growth of 9% in 2025, exceeding total company growth. The economic impact is twofold: higher revenue per customer and stickier relationships that insulate against pricing pressure from competitors like Steris.

Financial Performance & Segment Dynamics: Margin Expansion Despite Headwinds

Sotera’s 2025 results validate the durability thesis. Consolidated revenue grew 5.7% to $1.16 billion, marking the 20th consecutive year of growth. More telling is the margin trajectory: adjusted EBITDA margins expanded 120 basis points to 51%, driven by pricing discipline and operational leverage. This margin level reflects the essential nature of services where customers prioritize reliability over cost.

Sterigenics delivered $755.8 million in revenue (+8.3%) with segment income of $412.9 million (+9.2%). The 54.6% margin expanded despite absorbing inflation and facility enhancement costs related to NESHAP compliance. Growth was balanced: 4.1% pricing and 3.6% volume/mix, proving demand recovery in MedTech and bioprocessing is real. Management’s commentary that discussions about in-sourcing have “slowed down” due to the NESHAP extension reveals a critical dynamic: regulatory complexity actually strengthens Sotera’s value proposition, as customers prefer outsourcing compliance risk to a specialized provider.

Nordion posted $187.6 million in revenue (+8.2%) with $107.6 million segment income (+6.3%). The 57.3% margin remains the highest in the company. Q4 2025 revenue declined 12.3% due to Co-60 harvest timing, a predictable cyclicality that doesn’t reflect demand weakness. The 25-year license renewal from the Canadian Nuclear Safety Commission provides regulatory certainty through 2050, a moat that no competitor can replicate without a decade-long approval process.

Nelson Labs presents a tale of operational discipline amid revenue headwinds. Revenue declined 3.9% to $220.2 million due to a 10.2% drop in Expert Advisory Services (EAS), which management expects to ease in Q1 2026. Yet segment income grew 6% to $73.3 million, expanding margins 312 basis points to 33.3%. This margin expansion, driven by lab optimization and favorable pricing in core testing, demonstrates management’s ability to restructure the cost base. Core lab testing volumes are growing, fueled by new regulations like USP 665 for bioprocessing components.

The balance sheet reinforces the investment case. Net leverage improved to 3.2x from 3.7x in 2024, progressing toward the 2-3x long-term target. September 2025’s term loan repricing saved $13 million annually in interest, while the April 2025 revolver amendment added $175 million in liquidity and extended maturity to 2030. With $940 million in available liquidity and $200+ million in free cash flow, the company has ample firepower to fund the $175-225 million capex budget for 2026. The declining capex trajectory supports management’s $500-600 million cumulative free cash flow target for 2025-2027.

Outlook, Management Guidance, and Execution Risk

Management’s 2026 guidance projects $1.233-1.251 billion in revenue (5-6.5% constant currency growth) and $632-641 million in adjusted EBITDA (5.5-7% growth). These targets embed several critical assumptions. First, total company pricing is expected near the midpoint of the 3-4% long-term range, implying continued pricing power despite potential competition from Steris’s scale or in-sourcing trends.

Second, volume growth depends on MedTech and bioprocessing recovery continuing through 2026. Management’s commentary indicates the inventory correction that pressured 2023-2024 results has abated. The bioprocessing segment, while small, is growing significantly from a low base, providing a new growth vector.

Third, the X-ray facility opening in the second half of 2026 is expected to have a minor impact in 2026, with acceleration in 2027 and 2028. Management targets 40% utilization before breaking ground, but admits this facility is lighter on pre-commitments and will generate below the 20% IRR target initially.

Fourth, foreign currency is expected to contribute 100 basis points to growth, weighted to the first half. This is a tailwind that could help offset any volume softness.

The guidance does not assume any M&A, yet management notes the fragmented nature of the testing market and Sotera’s strong position to consolidate. With net leverage at 3.2x and heading toward the 2-3x target, the company could have capacity for accretive acquisitions by 2027.

Risks and Asymmetries

The investment thesis faces three material risks. EO litigation remains the most significant. While over 1,000 claims have been settled, approximately 450 personal injury and 305 property devaluation claims remain pending in Georgia, with trials scheduled for 2026-2027. In California, approximately 120 claims related to Vernon facilities are pending, with trials set for 2027. New Mexico’s Attorney General seeks injunctive relief and damages, with trial set for July 2026. The key monitor is whether settlement values remain in the $30-35 million range per batch of claims, which the company can fund from cash flow.

NESHAP regulatory risk presents a second challenge. While the July 2025 two-year exemption provides breathing room, a January 2026 complaint seeks to invalidate it, potentially accelerating compliance timelines. Management is spending $51 million in 2026 on facility enhancements, but if the exemption is overturned, capex could spike.

Cobalt-60 supply concentration is a third risk. While Russian supply risk has diminished, the company still depends on a limited number of nuclear reactors. A major outage or geopolitical event could disrupt supply. The Westinghouse/PSEG partnership and Darlington investment mitigate this, but the 2-3 year timeline for new supply means near-term vulnerability remains.

On the upside, tariff-driven reshoring could accelerate growth. If med device manufacturing returns to the U.S., Sotera’s domestic facility footprint positions it to capture incremental volume. The USMCA exemption for Co-60 gives Nordion a cost advantage over potential international competitors.

Competitive Context and Positioning

Sotera’s competitive positioning reveals both strengths and vulnerabilities relative to key rivals. Versus Steris, Sotera’s 51% EBITDA margins dramatically exceed Steris’s mid-20s, reflecting the pricing power of gamma irradiation and the recurring nature of Co-60 supply contracts. However, Steris’s $5.46 billion revenue base and 100+ facilities provide scale advantages.

Against Charles River, Sotera’s Nelson Labs segment demonstrates superior profitability (33% margins vs CRL’s low-teens operating margins) and stability, with core testing volumes growing despite CRL’s -0.9% revenue decline in 2025.

Relative to Solventum (SOLV), Sotera’s pure-play service model generates higher margins (51% vs 7% operating margin) and more predictable cash flow, though SOLV’s consumables business provides product-based revenue that may be more defensible in a downturn.

Sotera’s moats are defensible. The proprietary Co-60 supply is a genuine differentiator that translates to 5-10% pricing premiums, but it also creates concentration risk. The global facility network with pre-approved FDA licenses provides 20-30% faster validation times than new entrants.

Valuation Context

At $13.13 per share, Sotera Health trades at an enterprise value of $5.67 billion, representing 10.24x TTM EBITDA and 4.87x revenue. These multiples stand at meaningful discounts to direct peers: Steris trades at 14.71x EBITDA, Charles River at 11.70x, and Solventum at 13.09x. The discount is more pronounced when considering margin differentials—Sotera’s 51% EBITDA margins are more than double Steris’s mid-20s.

The price-to-free-cash-flow ratio of 25.03x reflects the elevated capex period for NESHAP compliance. As capex declines from $138 million in 2025 toward $110 million by 2027, free cash flow should expand. Management’s target of $500-600 million in cumulative free cash flow over 2025-2027 implies an average of $167-200 million annually, which would place the stock at 18-22x forward FCF.

William Blair’s analysis highlights the disconnect: despite similar growth outlooks, SHC trades at 10.7x 2026E EBITDA, roughly five turns below peers. The firm sees potential for 45% upside if the stock re-rates toward its long-term average forward EBITDA multiple of 12.6x. This re-rating depends on continued litigation resolution and execution on the X-ray facility.

Conclusion

Sotera Health represents a rare combination of mission-critical infrastructure, durable competitive moats, and temporary valuation discount. The company’s 20-year growth streak through multiple crises demonstrates the non-discretionary nature of its sterilization and testing services, while its 51% EBITDA margins and vertical integration of Cobalt-60 supply create pricing power that peers cannot match. The EO litigation overhang has progressed from existential threat to manageable risk, with settlements occurring at predictable values and favorable verdicts supporting management’s defense strategy.

The investment thesis hinges on the pace of litigation resolution and successful ramp of the X-ray facility. Continued settlements in the $30-35 million range per batch of claims would confirm the risk is quantifiable and fundable from cash flow, likely catalyzing a re-rating toward peer multiples. X-ray facility execution would complete the modality portfolio and address commercial market demand, supporting long-term growth beyond the core medical device segment.

Trading at 10.24x EBITDA versus peers at 12-15x, the market offers a discount for a business that has proven its resilience and is entering a period of enhanced free cash flow generation as capex normalizes. With net leverage improving toward the 2-3x target and $500-600 million in cumulative free cash flow expected over the next three years, Sotera has the financial flexibility to de-risk the balance sheet further, pursue accretive acquisitions, or return capital to shareholders. For investors willing to look through the litigation noise, SHC offers exposure to essential healthcare infrastructure at a price that doesn’t reflect its structural advantages or earnings power.